



Resolution n°17-2023-e

Cost Extension for the Project “Adherence Support Coalition to End TB” (ASCENT)

Recalling Unitaid Board Resolution R12-2019-e in which the Board authorized the Executive Director to commit up to US\$ 13,998,007 for the project entitled “Adherence Support Coalition to End TB” (ASCENT) (the “Project”) to be implemented by Koninklijke Nederlandse Centrale Vereniging tot bestrijding der Tuberculose (“KNCV”) for a 3.5-year period;

Noting that in 2022, the Secretariat approved a twelve-month no-cost extension to the duration of funding for the Project, ending on 31 December 2023;

Recalling that in June 2023, the Board endorsed an Area for Intervention (AFI) to *Accelerate and promote responsible introduction of new drug-resistant Tuberculosis (DR-TB) drugs and regimens*;

Acknowledging the opportunity to achieve rapid impact within this AFI, through the expansion of the Project to support the rapid introduction of newly recommended DR-TB regimens, including BPAL/M; and

Taking into account the assessment by the PRC and the Secretariat’s recommendations with respect to the Project extension proposal submitted by KNCV, the Board authorizes, subject to the availability of funds, the Executive Director to commit additional funding of up to US\$ 11,000,000 for the Project and to extend the duration of funding for the Project up to 30 September 2025, subject to the signature of a formal amendment to the legal agreement for the Project.

The additional funding and extension to the Project shall not apply to the original outputs 1-4 and is conditional upon signature of a formal amendment to the grant agreement for the Project.

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 2 October 2023